Can Semaglutide Cause Constipation? Who's at Risk

Can Semaglutide Cause Constipation? Here's Who's Most Likely to Get It

Constipation is one of the more predictable digestive side effects of semaglutide, showing up in about 24% of people on the drug in Wegovy's pivotal trials versus 11% on placebo.¹ That risk concentrates in a few identifiable places: where you are in dose-titration, how much fluid and fiber you're actually getting, your activity level, and your digestive history before you started. Knowing which of those apply to you says more about your actual odds than the topline trial number does.

How Common Is Constipation on Semaglutide?

Constipation shows up often enough in semaglutide's own prescribing data that it's not a fringe complaint. The Wegovy label lists it in about 24% of users at the 2.4 mg dose, compared with 11% on placebo. Any gastrointestinal adverse reaction, a broader category that includes constipation alongside nausea, diarrhea, vomiting, abdominal pain, dyspepsia, and several others, hit 73% versus 47%.¹ Roughly 6.8% of people on semaglutide stopped the drug permanently because of side effects overall, versus 3.2% on placebo.¹

A pooled, post-hoc tolerability analysis of three of the pivotal STEP trials (2,117 people on semaglutide, 1,262 on placebo, funded by Novo Nordisk with several authors employed by or consulting for the company) found that constipation doesn't just happen more often, it also sticks around longer.² Median duration was 47 days on semaglutide versus 35 days on placebo, compared with just 2 to 8 days for nausea, vomiting, or diarrhea.² Nausea, diarrhea, and vomiting rates peaked around week 20 before declining, but constipation followed a different timeline: its prevalence across the trial population leveled off earlier, around week 10, while you're still mid-titration, and then stayed elevated versus placebo through the full 68-week trial rather than tapering off.² This is a population-level pattern rather than a guarantee for any one person: it means constipation stayed common across the group as a whole for longer than the other GI complaints did, not that every individual case runs the full 68 weeks.

The Dose-Titration Window Carries Extra Risk

Semaglutide slows gastric emptying, an effect linked to how the drug reduces appetite and food intake.³ A clinical review of GLP-1 drugs found this gastric-emptying slowdown can partially fade with continued use, though the data only extends to about 16 weeks and what happens beyond that point isn't established either way.³ The same review found that GI symptoms in general don't reliably track with how much gastric emptying is actually delayed, so ongoing discomfort isn't something you can diagnose on your own from symptoms alone.³

The STEP-trial data above shows constipation becoming common early, around the population-wide week-10 plateau, which falls within the standard titration window; it doesn't establish what happens for any one person's symptoms as they move through later dose increases. If constipation shows up early in your own titration and doesn't fully let up, that's consistent with the trial data above, not a sign something unusual is happening to you specifically.

Dehydration and Low Fiber Intake Compound the Slowdown

Appetite suppression is the whole point of the medication, but it can compound the constipation risk indirectly: the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists insufficient fluid intake and insufficient dietary fiber among the recognized causes of constipation in general, alongside low physical activity, certain medications, aging, and pregnancy.⁴ If eating less on semaglutide also means you're drinking and eating less fiber-rich food overall, you may be adding those two risk factors on top of the drug's own slowing effect, not instead of it.

Fiber does help, with one trade-off. A 2022 systematic review and meta-analysis of fiber supplementation for chronic constipation (in a general adult population, not semaglutide users specifically) found fiber increased weekly bowel movements by about 1.19 more per week than placebo in a sensitivity analysis, and psyllium alone did better, at roughly 3.08 more per week.⁵ Flatulence severity was significantly worse with fiber supplementation in that same analysis, while bloating severity showed no significant difference from placebo.⁵ Fiber is a real lever, and more gas is the more likely trade-off, not necessarily more bloating.

Federal dietary reference intake tables put the daily fiber target at 25 g for women 19 to 50, dropping to 21 g for women 51 and older.⁶ It's a lower bar than the one for younger women, but appetite suppression from semaglutide can make even that reduced target harder to hit if your meals have gotten smaller across the board.

Inactivity Is a Contributing Factor, Not the Deciding One

Low physical activity is on NIDDK's list of recognized constipation causes,⁴ and fatigue or nausea from a GLP-1 medication can understandably make you move less some days. Staying reasonably active is a sensible, low-risk lever to pull.

The link is weaker at the individual level than that list might suggest. A population-based study of adults age 65 to 104 measured colonic transit directly and found that age, sex, physical activity level, and dietary fiber intake did not statistically distinguish people with functional constipation from symptom-free controls; only laxative use correlated with slower transit, which the study's authors could not establish as cause versus effect (it may simply mark people who already had slow transit and were treating it).⁷ That study was done in a much older population than most semaglutide users, so it doesn't mean activity and fiber don't matter. It does mean no single lifestyle factor guarantees you'll avoid constipation on this medication. If you're already doing those things and still getting backed up, that lines up with the evidence, rather than pointing to something you're doing wrong.

Your Digestive History Before Starting Matters

If you already had sluggish bowel habits, three or fewer bowel movements a week, or a diagnosis like IBS-C before starting semaglutide, you're adding the drug's slowing effect on top of a baseline that was already running slow. That exact profile, three or fewer complete bowel movements a week, is the enrollment criterion used in one of the human trials on Bifidobacterium animalis subsp. lactis HN019, a probiotic strain studied specifically for chronic constipation.⁸

The evidence for that strain is mixed: don't assume any probiotic will reliably fix a pre-existing slow-transit problem. An earlier 28-day trial in 228 adults with functional constipation, funded by DuPont Nutrition & Health (HN019's manufacturer at the time, with two authors as DuPont employees), found no significant difference on its pre-specified primary or secondary endpoints; only in an after-the-fact subgroup of people with especially infrequent bowel movements at baseline did stool frequency improve significantly, and straining eased only at the higher of two doses tested.⁹ An 8-week trial of 229 adults with functional constipation (median age 45, roughly 85% female), funded by Danisco/IFF (the company that now markets HN019), found HN019 did not outperform placebo on its primary endpoint of weekly complete spontaneous bowel movements.⁸ A manufacturer-funded trial publishing a null primary result on its own ingredient is notable. Two secondary measures, abdominal pain and bloating, did improve, though the hierarchical testing plan had already stopped after the primary endpoint failed, so those secondary results count as exploratory rather than confirmed.⁸ A planned subgroup analysis in the same trial checked whether age, sex, baseline fiber intake, or smoking status changed the response and found no significant differences on any of them.⁸

A sluggish baseline is a real risk multiplier worth flagging to your prescriber. No single supplement reverses it overnight, but HN019's track record on transit time and comfort is exactly why we built it into our own daily formula, more on that below.

Other Medications and Conditions Can Stack the Risk

NIDDK's list of constipation causes also includes several categories of medication some people take alongside a GLP-1 drug: narcotic pain medicines, anticholinergics and antispasmodics, iron supplements, calcium channel blockers, and antacids containing aluminum or calcium, along with underlying conditions like diabetes and hypothyroidism.⁴ If you're managing any of those alongside semaglutide, you're layering risk factors rather than dealing with just one.

A retrospective study of 215 adults with type 2 diabetes starting semaglutide looked specifically at what predicted GI side effects (a combined category covering abdominal pain, distension, diarrhea, nausea and vomiting, and reduced appetite, not constipation as its own outcome) and found three independent predictors by logistic regression: a concurrent digestive disorder (roughly 4.5 times the odds), alcohol consumption (roughly 3 times the odds), and taking an alpha-glucosidase inhibitor like acarbose at the same time (roughly 3 times the odds).¹⁰ It's a single-center study that hasn't been externally validated, it was done in people with type 2 diabetes rather than a weight-management population, and it measured a broader GI-symptom composite rather than constipation on its own, so treat it as an early signal, not a confirmed risk multiplier. It's consistent with the broader medication list above: several risk factors for slower digestion can stack in the same person.

When Constipation Is a Medical Emergency, Not a Side Effect to Manage at Home

Most semaglutide-related constipation is uncomfortable but manageable. A smaller number of presentations need urgent care instead of a supplement:

• Severe or worsening abdominal pain, especially radiating to the back, with nausea, vomiting, fever, chills, or yellowing of the skin or eyes: this combination can signal pancreatitis and needs prompt medical attention.¹¹
• Upper-abdominal pain lasting several hours along with fever, chills, jaundice, dark urine, or pale stools: this pattern can point to a gallbladder problem and also warrants prompt care.¹²
• No bowel movements or gas for an extended stretch, paired with severe cramping, vomiting, or a visibly distended abdomen: this can indicate a bowel obstruction, which needs urgent evaluation, not more fiber or a laxative at home.¹³ Semaglutide's label lists ileus among the reactions reported after the drug reached the market; that kind of post-marketing report can't establish how often it happens or whether the drug caused it, so it isn't accurate to call it "rare" or any other frequency label, only that it's been reported and isn't well quantified.¹

Never adjust or stop a prescribed GLP-1 dose on your own to manage a side effect. That decision belongs with the prescriber who's tracking your full picture.

Building a Routine That Lowers Your Risk

Most of the risk factors covered here point toward the same practical response: a daily routine around fluid, fiber, movement, and gut support, kept up before you're backed up, not just after. That's the exact gap our two products are built to close.

WonderBiotics Probiotics for Gut Health pairs HN019 and NCFM with ten other strains and FOS as a prebiotic, formulated specifically as a GLP-1 companion for routine digestive comfort, something you take daily whether or not you're mid-titration, built around the strain with the deepest human research base for bowel regularity we could find, rather than a generic multi-strain blend borrowed from another category. It's designed to support a regular routine alongside your medication, not to replace addressing red-flag symptoms with your doctor.

If fiber intake is your bigger gap, WonderBiotics Daily Fiber Mix is the more direct tool: built around Fibersol soluble corn fiber, partially hydrolyzed guar gum, and psyllium husk, with kale fiber, FOS, polydextrose, and white kidney bean powder rounding it out. Because fibers like psyllium and FOS can produce gas as your gut adjusts, start at one 6 g sachet rather than the full three, the same gradual approach the fiber research above supports, not a reason to skip fiber altogether.

A routine you actually keep up on the weeks your appetite is lowest tends to matter more than any single ingredient. If constipation is new, severe, or paired with any of the warning signs above, that's a conversation for your prescriber, not something to wait out.

References

1. Wegovy (semaglutide) injection, solution, prescribing information. DailyMed, setid f5e548d0-cc79-4c34-a3f5-e20a5b8b6564, Novo Nordisk. dailymed.nlm.nih.gov
2. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551. PMID 34514682. doi.org
3. Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2025;110(1):1-15. doi:10.1210/clinem/dgae719. doi.org
4. Symptoms & Causes of Constipation. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). niddk.nih.gov
5. van der Schoot A, Drysdale C, Whelan K, Dimidi E. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Clin Nutr. 2022;116(4):953-969. doi:10.1093/ajcn/nqac184. PMID 35816465. doi.org
6. Dietary Reference Intakes: Macronutrients Summary Table. National Academies of Sciences, Engineering, and Medicine, via NCBI Bookshelf (NBK545442). ncbi.nlm.nih.gov
7. Evans JM, Fleming KC, Talley NJ, Schleck CD, Zinsmeister AR, Melton LJ 3rd. Relation of colonic transit to functional bowel disease in older people: a population-based study. J Am Geriatr Soc. 1998;46(1):83-87. PMID 9434670. PubMed
8. Cheng J, Gao C, Ala-Jaakkola R, Forssten SD, Saarinen M, Hibberd A, Ouwehand AC, Ibarra A, Li D, Nordlund A, Wang Y, Shen X, Peng H, Wan X, Meng X. Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(10):e2436888. doi:10.1001/jamanetworkopen.2024.36888. PMID 39356506. doi.org
9. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: a double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. doi:10.1080/19490976.2017.1412908. PMID 29227175. doi.org
10. Yue D, Hua X, Zhu L, Wang J, Gu L, Yuan Z, Jian W, Chen Y, Meng G. Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2025;16:1684395. doi:10.3389/fendo.2025.1684395. PMID 41255528. doi.org
11. Pancreatitis - Symptoms & Causes. NIDDK. niddk.nih.gov
12. Gallstones - Symptoms & Causes. NIDDK. niddk.nih.gov
13. Intestinal obstruction - Symptoms and causes. Mayo Clinic. mayoclinic.org